louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04947332: Auto-inoculation of a Wart in Multiple Viral Warts
Official title: Effectiveness of Auto-inoculation of a Wart in Multiple Viral Warts, in Tertiary Care Hospital : A Single Arm Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Viral Wart
Delayed Hypersensitivity
Keywords: Autoinoculation
Viral Warts
Hypersensitivity
Immunology
Lead sponsor: Pak Emirates Military Hospital
Sponsor class: OTHER
First posted: 2021-07-01
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A single arm study
Primary purpose: TREATMENT

Brief summary: This study is being conducted to see effectiveness of auto-inoculation of a wart in multiple viral warts. Patients with recurrent, multiple warts of all types, are being recruited for the study. A wart is excised, minced and then inoculated in a subcutaneous pocket made on the volar aspect of forearm. Patients are to be reviewed after every 4 weeks to note any reduction in number warts.

Detailed description: A single arm, Phase 1, Clinical Study

Eligibility criteria: Inclusion Criteria:

* Individuals having 5 or warts
* Individuals having any types of warts

Exclusion Criteria:

* Individuals using any other treatment for warts

Primary outcomes:
measure: Complete Clearance of Warts
timeFrame: 12 weeks
measure: Incomlete Clearance of Warts
timeFrame: 12 weeks
measure: Non Responders
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Pak Emirates Military Hospital
state: Punjab
Study officials:
affiliation: Head of Department
name: Nadia Iftikhar, MBBS, FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT00449332: Early Indicators of Chronic Rejection in Lung Transplant
Official title: Role of Inflammatory and Fibroproliferative Cytokines in the Pathogenesis of Bronchiolitis Obliterans Syndrome-OP in Lung Transplant Recipients.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Chronic Rejection in Lung Transplant
Cytokine Production in Bos Post Lung Transplant
Keywords: Chronic rejection, lung transplant, cytokines, bos
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2007-03-20
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Post lung transplant patients

Brief summary: The purpose of this research is to discover the different patterns of cytokine production in patients who may develop Bronchiolitis Obliterans Syndrome-0p (BOS-0p) which means ongoing rejection. This is an early indicator of chronic rejection in lung transplant recipients. These cytokines can be detected in the bronchoalveolar (lung) and tissue samples of lung transplant recipients.

Detailed description: Lung transplant recipients are routinely followed in clinic every three months after the first year post-transplant. Spirometry with measurement of FEV1, FVC and FEF25-75 are obtained at each visit. In addition, lung transplant recipients undergo surveillance bronchoscopy at one, three, six, nine and twelve months. All bronchoscopy specimens that are obtained for this study will be obtained during bronchoscopies that were scheduled per the physician caring for the patient. An extra 90 cc of sterile solution will be instilled into bronchus and two extra transbronchial biopsies will be performed in addition to the routine bronchoscopic procedure. Routinely, 4-8 transbronchial biopsy samples are obtained from the transplanted lung. Two specimens will be randomly selected for study and the rest will undergo routine histopathologic study. The study biopsies will be set aside and processed. The study visits for this research will occur at the same time as standard of care post transplant visits. We will collect subject's history,demographic of subject's transplant data,donor procurement information, physical exam information, pregnancy tests,blood test and spirometry results from the visits mentioned above.

Eligibility criteria: Inclusion Criteria:

* Lung transplant recipients between the ages of 18 and 65 years old
* All patients must be able to give written informed consent

Exclusion Criteria:

* Lung transplant recipients who are unable to undergo bronchoscopy
* Lung transplant recipients who are unable to give informed consent

Primary outcomes:
measure: cytokines, chemokines and T cell subsets associated with BOS
timeFrame: 12/2013
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Sangeeta M Bhorade, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05635032: Fibrosing ILD Biomarkers That Rule Acceleration
Official title: Host-microbiome Interactions in the Quest for Fibrosing ILD Biomarkers That Rule Acceleration
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pulmonary Fibrosis
Sarcoidosis
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
Collaborators: name: Centro Hospitalar De São João, E.P.E.
name: Instituto de Investigação e Inovação em Saúde (i3S)
name: Fundação para a Ciência e a Tecnologia
First posted: 2022-12-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be recruited from the Interstitial Lung Diseases unit of Centro Hospitalar Universitário de São João (Porto, Portugal).

Brief summary: FIBRALUNG is a prospective cohort study with biobank of samples from patients with pulmonary fibrosis, aiming to explore the molecular determinants of different clinical outcomes, acute exacerbations and mortality. We expect to gain deeper insight into fibroproliferative common pathways, particularly between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis, paving the way for new biomarkers that reflect the progressive phenotype, that eventually will support new targeted therapies.

Other idiopathic interstitial pneumonias, connective tissue disease-related interstitial lung diseases and sarcoidosis patients will be also recruited and their biological samples stored for further analyses.


Eligibility criteria: Inclusion Criteria:

* Patients aged between 18-80 years
* People undergoing blood collection, lung biopsy and/or BAL as part of their diagnostic workup
* Willingness to undergo the follow-up protocol evaluations
* Treatment-naïve for disease-modifying drugs
* An HRCT scan performed within the last 12 months showing ≥10% fibrosis extent of the lungs

Exclusion Criteria:

* People who cannot give informed consent
* Pregnancy

Primary outcomes:
measure: Discover biomarkers in progressive pulmonary fibrosis
timeFrame: 36 months
Secondary outcomes:
measure: Change in microbiome profile in progressive pulmonary fibrosis
timeFrame: 24 months
Other outcomes:
measure: Variation in Computed Tomography Lung Densitometry
timeFrame: 36 months
measure: Proportion of patients varying FVC ⩾5% predicted within 1 year of follow-up
timeFrame: 36 months
measure: Proportion of patients varying DLCO ⩾10% predicted within 1 year of follow-up
timeFrame: 36 months
measure: Time to progression or exacerbation
timeFrame: 36 months
measure: Survival
timeFrame: 36 months
Locations:
city: Porto
country: Portugal
facility: Centro Hospitalar Universitário São João
Study officials:
affiliation: Universidade do Porto
name: Helder Novais Bastos, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01459432: Understanding Immunity Persistence After Adolescent MenC Vaccination
Official title: A Study to Evaluate the Persistence of Antibody Seven Years After a Booster Dose of Either a Glycoconjugate or a Polysaccharide Vaccine Against Serogroup C Neisseria Meningitidis Given to Adolescents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Antibody Persistance After Booster Dose of Men C Vaccine
Lead sponsor: University of Oxford
Sponsor class: OTHER
First posted: 2011-10-25
Enrollment: 134
Sex: ALL
Minimum age (years): 20
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young adults, approximately 20 - 23 years old.

Brief summary: The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age. Does seroprotection persist beyond teenage years and into the early twenties? This is the age group which is most likely to carry the organism and to transmit it to other members of the population. If a booster dose of MenC vaccine given to adolescents does produce protective levels of antibody which persist into early adulthood, this would strengthen the case for such a booster to be added to the UK routine immunisation schedule, to reduce the risk of a resurgence of the disease in the future.


Eligibility criteria: Inclusion Criteria:

* Participants who completed clinical study M14P2E1
* Participant who are willing to participate and who would be expected to comply with the requirements of the protocol
* Participants who have given informed consent for participation in the study

Exclusion Criteria:

* History of invasive meningococcal C disease (or any case of invasive meningococcal disease where the serotype was unknown)
* Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection
* Severe blood clotting disorders

Primary outcomes:
measure: Percentage of participants with rSBA titre ≥1:8 (correlate of protection).
timeFrame: 4 months
Secondary outcomes:
measure: Geometric mean titre (GMT) rSBA.
timeFrame: 4 months
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Oxford Vaccine Group
Study officials:
References:
citation: de Whalley PC, Snape MD, Plested E, Thompson B, Nuthall E, Omar O, Borrow R, Pollard AJ. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child. 2013 Sep;98(9):686-91. doi: 10.1136/archdischild-2013-303893. Epub 2013 Jul 13.
Clinical trial NCT01330732: Kyphosis Evaluation Using SPINESCAN®
Official title: The Correlation Between Radiological Evaluation of Kyphosis and Evaluation Using SPINESCAN®
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Kyphosis
Keywords: SPINESCAN®
kyphosis
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-04-07
Enrollment: 50
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.

Age: 7 and above.

Brief summary: The purpose of this study is to evaluate the accuracy of SPINESCAN® with standard lateral x-rays of the spine in patients monitored for kyphosis.

Detailed description: Kyphosis is usually a developmental deformity of the spine in the sagittal plane. Once diagnosed, serial X-rays are used for followup. These are usually required at yearly intervals.

SPINESCAN® is a computerized digital inclinometer, design for evaluating angular spine deformities.

Patients examined in the spine clinic with recent X-rays will be examined with SPINESCAN® and it's results compared with the classical radiological assessment.

Eligibility criteria: Inclusion Criteria:

* Patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
* Age: 7 years old and above.

Exclusion Criteria:

* Less than 7 years old.
* No informed consent.

Primary outcomes:
measure: Kyphosis degree (by SPINESCAN®)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf HaRofeh Medical Center
Study officials:
affiliation: Assaf-Harofeh Medical Center
name: Yigal Mirovsky, MD
role: STUDY_CHAIR
References:
citation: Ovadia D, Bar-On E, Fragniere B, Rigo M, Dickman D, Leitner J, Wientroub S, Dubousset J. Radiation-free quantitative assessment of scoliosis: a multi center prospective study. Eur Spine J. 2007 Jan;16(1):97-105. doi: 10.1007/s00586-006-0118-8. Epub 2006 May 17.
Clinical trial NCT02819232: Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs
Official title: Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infectious Keratitis
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2016-06-30
Enrollment: 442
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Infectious keratitis are favored by the circumstances causing the small trauma of the corneal epithelium, corneal surgery, corneal dryness under health system such as Sjögren's syndrome rheumatoid arthritis, or much more frequently wearing contact lenses. If the majority of infectious keratitis are favourable, some lead to serious injury of the cornea, or even corneal perforation which result an endophthalmitis. This unfavourable evolution may lead to blindness due to corneal damage, the endo-ocular lesions or enucleation of the eyeball. This negative evolution is encountered while the infectious keratitis due to tedious germs of difficult diagnosis such as nontuberculous Mycobacterial, fungal infections, fungal keratitis, amoebic keratitis, and certain viral keratitis. The microbiological diagnosis of routine is based on the systematic search for pathogens tedious from invasive sampling of cornea by vaccinostyle. We set up a new non-invasive corneal swab diagnostic method.

Detailed description: Primary Purpose: Compare the ability diagnostic of non-invasive sampling swab corneal versus the gold standard, (invasive vaccinostyle uptake) for the systematic search for pathogens tedious in corneal specimens.

Hypothesis:

The diagnostic strategy using a microbial testing of cornea method has a sensitivity of 90% and a specificity of 80% or more over the policy diagnostic using a sampling by vaccinostyle method.

Primary outcome measures: Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.

Eligibility criteria: Inclusion Criteria:

* Patient is more than 18 years old.
* Patient with a prescription of a microbiologic diagnostic of keratitis
* Patient who do not declined to have his medical records reviewed for research
* Patient with health insurance

Exclusion Criteria:

* minor patient (\<18 years).
* Pregnant or breastfeeding women.
* Major Patient under guardianship.
* Patient in vital emergency.
* Private Patient liberty or under court order.
* Patient refusing to sign the informed consent form

Primary outcomes:
measure: Sensitivity, specificity, positive and negative predictive values, Diagnostic odds ratio.
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hopitaux de Marseille
Study officials:
affiliation: Assistance Publique - Hôpitaux de Marseille
name: Michel Drancourt, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004832: Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lambert-Eaton Myasthenic Syndrome
Keywords: Lambert-Eaton myasthenic syndrome
neurologic and psychiatric disorders
rare disease
Lead sponsor: FDA Office of Orphan Products Development
Sponsor class: FED
Collaborators: name: Duke University
First posted: 2000-02-25
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS).

II. Determine the side-effects and benefits associated with DAP.

Detailed description: PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to receive 3,4-diaminopyridine (DAP) or placebo orally 3 times daily for 5 days, after which treatment is discontinued and patients are observed for at least 24 hours. At the end of the blinded study, patients may then elect to take open label DAP orally 3 times daily for 6 months; those who do so are monitored for clinical effects and side effects for at least 6 months.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Lambert-Eaton myasthenic syndrome (LEMS) based on weakness that predominates in proximal limb muscles and electromyography (EMG) findings of small amplitude muscle responses to nerve stimulation, which decrease further during nerve stimulation at 5 Hz and which increase at least 2-fold after maximum voluntary contraction of the muscle for 10-20 seconds Quantified Myasthenia Gravis (QMG) clinical score at least 5 --Prior/Concurrent Therapy-- Chemotherapy: No concurrent chemotherapy Endocrine therapy: Patients receiving immunosuppressants must be on the same dose of medication for at least 3 months prior to study entry Radiotherapy: No concurrent radiotherapy Surgery: No concurrent surgery Other: Patients receiving cholinesterase inhibitors must discontinue the medication at study entry if possible, or else be on the same dose of medication for at least 1 month prior to study entry --Patient Characteristics-- Hematopoietic: No significant hematologic disease Hepatic: No significant hepatic disease Renal: No significant renal disease Cardiovascular: No cardiac arrhythmia or significant cardiac disease Neurologic: No seizure disorder Other: Not pregnant Negative pregnancy test required of fertile women Effective contraception required of fertile women

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Donald B. Sanders
role: STUDY_CHAIR
References:
Clinical trial NCT06283732: A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.
Official title: A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Digestive System Disease
Keywords: Dietary Supplements
Digestive Health
Well-being
Energy Levels
Lead sponsor: Amway Corp
Sponsor class: INDUSTRY
Collaborators: name: Citruslabs
First posted: 2024-02-28
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The study aims to evaluate the effectiveness of a dietary supplement (greens powder), on improving digestive health, quality of life, energy levels, and satiety over a 14-day period. Participants, aged 18-65 and experiencing mild digestive issues, will consume the greens powder daily and report outcomes through diaries and questionnaires.


Eligibility criteria: Inclusion Criteria:

* Male or female.
* Aged 18-65 years.
* Willing to comply with study requirements.
* No known allergies to the ingredients listed in the product.
* Self-reported mild digestive issues (e.g., occasional bloating, stomach discomfort, occasional constipation, or occasional diarrhea).
* Generally healthy - do not live with any uncontrolled chronic disease .

Exclusion Criteria:

* Pre-existing chronic conditions that would prevent adherence to the protocol, including oncological and psychiatric disorders.
* Known severe allergic reactions that require an Epi-Pen.
* Women who are pregnant, breastfeeding, or attempting to conceive.
* History of severe diagnosed digestive disorders (e.g., IBS, IBD, Crohn's disease) or gastrointestinal-tract surgeries.
* Unwillingness to follow the study protocol.
* Invasive medical procedure within the last three weeks or planning one during the study period.
* History of substance abuse.
* Current participation or planning to participate in another research study.
* Regular consumption of probiotics, fiber, or prebiotic supplements within 3 weeks of the study.
* Regular intake of medications that may interfere with the study or study product (e.g., anticoagulants, laxatives, sedatives, beta-blockers, anti-acids) .

Primary outcomes:
measure: Digestive Health Improvement
timeFrame: 14 days from the start of intervention
Secondary outcomes:
measure: Quality of Life and Well-being Enhancement
timeFrame: 14 days from the start of intervention
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Citruslabs
state: California
Study officials:
References: